SEC Tracker
Get the app

McKESSON MCK

McKESSON Q3 FY25: revenue $95.3B, up 18%; diluted EPS $6.95

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers McKESSON reported for Q3 FY25, the quarter ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$95.3B+18% from $80.9B in Q3 FY2410-Q income statement, on EDGAR
  2. Net income$879.0M+49% from $589.0M in Q3 FY2410-Q income statement, on EDGAR
  3. Diluted EPS$6.95+57% from $4.42 in Q3 FY2410-Q income statement, on EDGAR
  4. Cash and cash equivalents$1.1B−43% from $2.0B in Q3 FY2410-Q balance sheet, on EDGAR
  5. Cash from operations−$2.4B−1038% from $254.0M in Q3 FY2410-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when McKESSON files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 5122 and related industry codes: the same peer list as the financial tables.

  1. Cardinal Health CAH public float $48.2B, Dec 31, 2025
  2. Cencora COR public float $37.9B, Mar 31, 2025, over 18 months old
  3. Herbalife HLF public float $762M, Jun 30, 2025
  4. Nu Skin Enterprises NUS public float $390M, Jun 30, 2025
  5. DataMeds AI MEDS public float $27M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.